Lexology June 7, 2024
Pharmaceutical drug pricing and reimbursement continues to make headlines nationwide. In a recent development, Maryland’s Prescription Drug Affordability Board (PDAB) finalized its list of selected drugs for affordability review. The board will engage in what it contends will be a comprehensive “cost review” where it will seek public comments, additional information, and data over a 60-day period to determine if the selected drugs will be subject to state-prescribed upper payment limits.
Background
As we’ve previously covered on the blog, in response to rising prescription costs and overall state-level healthcare spending, 11 states to date, including Maryland and Colorado, have created drug affordability review boards to review certain high-cost prescription brand and generic drugs to determine if they should take action...
Today's Sponsors
Today's Sponsor